Arena And Vivus Take Divergent Paths To Respond To Obesity Setbacks
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
To little surprise, FDA has issued “complete responses” for two of the main competitors racing to develop new obesity drugs. While both drug candidates were knocked down on their first pass over by the agency, the similarities stop there.
You may also be interested in...
Further Phase III Data May Not Help Approvability Of Arena’s Lorcaserin
The latest Phase III results for Arena Pharmaceuticals’ lorcaserin give little clarity to the regulatory path forward for the drug and add concerns about the safety of the obesity pill.
Further Phase III Data May Not Help Approvability Of Arena’s Lorcaserin
The latest Phase III results for Arena Pharmaceuticals’ lorcaserin give little clarity to the regulatory path forward for the drug and add concerns about the safety of the obesity pill.
Vivus' Qnexa Gets "Complete Response" Letter From FDA
FDA wants more data on risk of birth defects, cardiovascular effects, but doesn't ask for new clinical trials - at least for now.